Stocknear Logo Stocknear
/
Popular
Login

Jaguar Health Inc.

11.06
3.00 (37.22%)
At close: Apr 25, 2025, 3:59 PM
10.89
-1.51%
After-hours: Apr 25, 2025, 05:58 PM EDT
37.22%
Bid 10.25
Market Cap 7.45M
Revenue (ttm) 11.69M
Net Income (ttm) -38.49M
EPS (ttm) -130.69
PE Ratio (ttm) -0.08
Forward PE -0.27
Analyst n/a
Ask 10.9
Volume 2,927,072
Avg. Volume (20D) 38,402
Open 8.22
Previous Close 8.06
Day's Range 8.22 - 15.48
52-Week Range 4.02 - 540.00
Beta 1.11

About JAGX

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer fo...

[Read more]
Industry Biotechnology
Sector Healthcare
IPO Date May 12, 2015
Employees 49
Stock Exchange NASDAQ
Ticker Symbol JAGX
Website https://jaguar.health
Full Company Profile

Next Earnings Release

Jaguar Health Inc. is scheduled to release its earnings on May 13, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
1 month ago
-47.74%
Jaguar Health shares are trading lower after the c... Unlock content with Pro Subscription
8 months ago
-10.83%
Jaguar Health shares are trading lower after the company reported worse-than-expected second-quarter results.
news image

1 week ago · accessnewswire.com

Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress

Crofelemer, a novel plant-based anti-secretory prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency (EMA) for both short bowel syndrome (SBS) and mi...

news image

1 week ago · accessnewswire.com

Jaguar Health Announces Significant Results in Breast Cancer Patients Accepted for Presentation at Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting

The statistically significant responder analysis results for Mytesi® (crofelemer) in the Phase 3 OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December 20...

news image

2 weeks ago · accessnewswire.com

Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product

Gelclair ® is the company's third commercialized prescription product Oral mucositis, also called "chemo mouth," a painful inflammation of the mouth's mucous membranes, has emerged as the most signifi...

news image

3 weeks ago · accessnewswire.com

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / April 4, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective April 3, 2025, the Company granted 3,600 res...

news image

3 weeks ago · accessnewswire.com

Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules

SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / April 1, 2025 / Jaguar Health, Inc. ( NASDAQ:JAGX ) ("Jaguar" or "the Company"), today announced the closing of its previously announced private placement...

news image

3 weeks ago · seekingalpha.com

Jaguar Health, Inc. (JAGX) Q4 2024 Earnings Call Transcript

Jaguar Health, Inc. (NASDAQ:JAGX ) Q4 2024 Earnings Conference Call March 31, 2025 8:30 AM ET Company Participants Conference Call Participants Operator Greetings, and welcome to the Jaguar Health Inv...

news image

3 weeks ago · accessnewswire.com

Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023

The total net revenue for the year ended December 31, 2024 of approximately $11.7 million for prescription and non-prescription products, including license revenue, increased approximately 20% versus ...

news image

4 weeks ago · accessnewswire.com

83.33% of Veterinary Oncologists Highlight Importance of Jaguar Health's FDA Conditionally Approved Canalevia-CA1 as a Non-Antibiotic Treatment for Chemotherapy-Induced Diarrhea (CID) in Dog's in New Survey

Canalevia®-CA1 (crofelemer delayed-release tablets) is the first and only treatment for CID in dogs to receive any type of approval from the FDA In dogs undergoing chemotherapy, as is the case with pe...

news image

4 weeks ago · accessnewswire.com

Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study

The statistically significant responder analysis results for Mytesi® (crofelemer) in the OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December 2024 poste...

news image

1 month ago · accessnewswire.com

Jaguar Health Presenting March 27 at Emerging Growth Conference and Holding Investor Webcast March 31 Regarding Q4 2024 Financials & Near-Term Catalysts

Click here to register for Jaguar's March 27 virtual presentation at the Emerging Growth Conference Click here to register for Jaguar's March 31 investor webcast Company plans to file its annual repor...

Create Price Alert on JAGX

Your price alert will notify you when the stock price is above 11.06.

Add to Watchlist